Kappa light chain nephropathyPlasma exchange therapyMembrane plasma separationCalcium-free dialysisOften the diagnosis "light chain nephropathy" is not made before renal failure has developed. In the past these patients had a poor prognosis. Special features of this disease and improvement of renal ...
The most promising second line drugs are venetoclax [for t(11;14)] and pomalidomide, with several others in the pipeline, including antibody-drug conjugates. Minimal residual disease will emerge as a new endpoint for drug development and will potentially guide treatment duration....
Light chain (AL) and secondary (AA) amyloidosis usually present as a systemic disease frequently involving the kidney and leading to ESRD. Data regarding p... G Bollee,B Guery,D Joly,... - 《Clinical Journal of the American Society of Nephrology Cjasn》 被引量: 80发表: 2008年 加载更多来...
9,10]. The management of PMD conditions remains a poorly researched area and there is little expert advice available for the treatment of specific aspects of mitochondrial disease [8,9,10]. The involvement of several organs can pose additional patient management ...
Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomi...
Lenalidomide is a mostly utilized immunomodulatory drug that can upregulate the T cell activity by inducing the T cell proliferation, elevating the expression of kappa-light-chain-enhancer of activated B cells (NF-κB) nuclear factor, and phosphorylating the CD28 costimulatory molecule in T cells. ...
NAFLD nonalcoholic fatty liver disease NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells NLRP3 nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 NO nitric oxide NOD1 nucleotide-binding oligomerization domain 1 NPs nanoparticles O2· superoxide...
Many genetic mutations in sarcomeric proteins, including the cardiac myosin regulatory light chain (RLC) encoded by the MYL2 gene, have been implicated in familial cardiomyopathies. Yet, the molecular mechanisms by which these mutant proteins regulate cardiac muscle mechanics in health and disease re...
mutations in kinase domains (e.g.,EGFRexon 20 insertion for resistance to anti-EGFR therapy38), isoform switching (e.g., BRAF/CRAF switching for resistance to anti-BRAF therapy40), and metabolic reprogramming40during disease development are involved in primary resistance to molecular targeted thera...
(IL-6) mediated by nuclear factor kappa-light-chain-enhancer of activated B cells NF-κB during HIV infection, as demonstrated in vitro [29]. Additional CSF markers for neuronal injury currently being investigated in the context of HAND are quinolinic acid, CSF total Tau concentrations, CSF ...